These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 11790159)

  • 21. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
    Chapple CR; Baert L; Thind P; Höfner K; Khoe GS; Spångberg A
    Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.
    Lepor H
    Urology; 1998 Jun; 51(6):892-900. PubMed ID: 9609623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
    Nickel JC
    Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand.
    Arnold EP
    BJU Int; 2001 Jan; 87(1):24-30. PubMed ID: 11121988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
    Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
    Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
    Lee E; Lee C
    Br J Urol; 1997 Oct; 80(4):606-11. PubMed ID: 9352700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect.
    Lowe FC
    Clin Ther; 1997; 19(4):730-42. PubMed ID: 9377617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of tamsulosin in the treatment of urological diseases.
    Michel MC; de la Rosette JJ
    Expert Opin Pharmacother; 2004 Jan; 5(1):151-60. PubMed ID: 14680444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.
    Wilde MI; McTavish D
    Drugs; 1996 Dec; 52(6):883-98. PubMed ID: 8957159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
    Kirby RS
    BJU Int; 2003 Jan; 91(1):41-4. PubMed ID: 12614248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Narayan P; Evans CP; Moon T
    J Urol; 2003 Aug; 170(2 Pt 1):498-502. PubMed ID: 12853808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Gross AJ; Busse M; Leonard J; Schumacher H
    Prostate Cancer Prostatic Dis; 2005; 8(3):210-4. PubMed ID: 15883586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Schulman CC
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):771-82. PubMed ID: 18611117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    Wilt TJ; Howe W; MacDonald R
    BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.